Luminex eyes FDA approval for HSV 1&2 tests; Biocept rolls out BRAF mutation test;

> Luminex ($LMNX) submitted its 510(k) applications to the FDA for its HSV 1&2 test. Statement

> The companion diagnostics market is expected to reach $5.6 billion in 2019, according to a new report. Release

> San Diego, CA-based Biocept ($BIOC) launched its test for BRAF mutations in patients with melanoma. More

> Curetis is kicking off the next phase in a trial for a second-generation version of its diagnostic system for lower respiratory tract (LRT) infections. Statement

> Progenetics inked a deal with OncoDNA to distribute the company's products in Israel. Story (reg. req.)

And Finally… A new study comparing Ebola diagnostics approved for emergency use found that a test from bioMérieux's BioFire Diagnostics unit was faster and easier to use than other products. Abstract

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.